Trial · NCT00926380
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
NCT00926380, Phase 2, Completed, Massachusetts General Hospital; results first posted 2018-05-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis. Trials, record NCT00926380. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00926380
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
- NCT number
- NCT00926380
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 94 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Osteoporosis
- Interventions
- denosumab, teriparatide
- First posted
- 2009-06-23
- Last updated
- 2018-06-29
- Results first posted
- 2018-05-08
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Spine Bone Density From Baseline to 2 Years | Baseline and 2 years |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Spine Bone Density From Baseline to 2 Years | Baseline and 2 years | percent change | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Spine Bone Density From Baseline to 2 Years | Denosumab ONLY | 8.3 | Standard Error 3.4 | percent change | |
| Change in Spine Bone Density From Baseline to 2 Years | Teriparatide (Forteo®) ONLY | 9.5 | Standard Error 5.9 | percent change | |
| Change in Spine Bone Density From Baseline to 2 Years | Denosumab and Teriparatide (Forteo®) | 12.9 | Standard Error 5.0 | percent change |
Source ClinicalTrials.gov
Participant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Year 1 | STARTED | Denosumab ONLY | 33 | |
| Year 1 | STARTED | Teriparatide (Forteo®) ONLY | 31 | |
| Year 1 | STARTED | Denosumab and Teriparatide (Forteo®) | 30 | |
| Year 1 | COMPLETED | Denosumab ONLY | 33 | |
| Year 1 | COMPLETED | Teriparatide (Forteo®) ONLY | 30 | |
| Year 1 | COMPLETED | Denosumab and Teriparatide (Forteo®) | 29 | |
| Year 1 | NOT COMPLETED | Denosumab ONLY | 0 | |
| Year 1 | NOT COMPLETED | Teriparatide (Forteo®) ONLY | 1 | |
| Year 1 | NOT COMPLETED | Denosumab and Teriparatide (Forteo®) | 1 | |
| Year 2 | STARTED | Denosumab ONLY | 33 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events21
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash | Skin and subcutaneous tissue disorders | Denosumab ONLY | 4 | 33 | |
| other | Rash | Skin and subcutaneous tissue disorders | Teriparatide (Forteo®) ONLY | 0 | 31 | |
| other | Rash | Skin and subcutaneous tissue disorders | Denosumab and Teriparatide (Forteo®) | 2 | 30 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Denosumab ONLY | 0 | 33 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Teriparatide (Forteo®) ONLY | 2 | 31 | |
| other | Reactions at injection site | Skin and subcutaneous tissue disorders | Denosumab and Teriparatide (Forteo®) | 0 | 30 | |
| other | Hypercalcemia | Endocrine disorders | Denosumab ONLY | 0 | 33 | |
| other | Hypercalcemia | Endocrine disorders | Teriparatide (Forteo®) ONLY | 0 | 31 | |
| other | Hypercalcemia | Endocrine disorders | Denosumab and Teriparatide (Forteo®) | 2 | 30 | |
| other | Nausea | Gastrointestinal disorders | Denosumab ONLY | 0 | 33 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Denosumab ONLY | ||
| Total, all-cause mortality | Teriparatide (Forteo®) ONLY | ||
| Total, all-cause mortality | Denosumab and Teriparatide (Forteo®) | ||
| Total, other adverse events | Denosumab ONLY | 4 | 33 |
| Total, other adverse events | Teriparatide (Forteo®) ONLY | 5 | 31 |
| Total, other adverse events | Denosumab and Teriparatide (Forteo®) | 4 | 30 |
| Total, serious adverse events | Denosumab ONLY | 1 | 33 |
| Total, serious adverse events | Teriparatide (Forteo®) ONLY | 2 | 31 |
| Total, serious adverse events | Denosumab and Teriparatide (Forteo®) | 1 | 30 |
Source ClinicalTrials.gov
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00926380
GET https://conductscience.org/api/trials/v1/NCT00926380/events?page=2